Abstract
Population studies have identified diabetes mellitus as a risk factor for cardiac and vascular events, with a common association with hypertension. Observational studies have consistently demonstrated blood glucose as a continuous cardiovascular risk factor. Experimental studies suggest that elevated blood glucose, through a range of biochemical pathways can promote atherogenesis and increase the tendency for thrombosis. The resultant state promotes occlusion of arterial flow and increase cardiovascular event rates. However, an unconvincing temporal relationship (raised blood glucose preceding cardiovascular events) and the limited impact of glucose reduction in patients with diabetes on cardiovascular events do not support blood glucose as a major cause of cardiovascular disease. In this review, we discuss the relationship between hyperglycaemia and a hypercoagulable state in diabetes and the implications of this relationship for the treatment of patients with diabetes, who also commonly have hypertension.
Keywords: Thrombosis, Insulin Resistance, Glucose, Endothelium, Diabetes
Current Pharmaceutical Design
Title: The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management
Volume: 12 Issue: 13
Author(s): Hoong S. Lim, Robert J. MacFadyen, George Bakris and Gregory Y.H. Lip
Affiliation:
Keywords: Thrombosis, Insulin Resistance, Glucose, Endothelium, Diabetes
Abstract: Population studies have identified diabetes mellitus as a risk factor for cardiac and vascular events, with a common association with hypertension. Observational studies have consistently demonstrated blood glucose as a continuous cardiovascular risk factor. Experimental studies suggest that elevated blood glucose, through a range of biochemical pathways can promote atherogenesis and increase the tendency for thrombosis. The resultant state promotes occlusion of arterial flow and increase cardiovascular event rates. However, an unconvincing temporal relationship (raised blood glucose preceding cardiovascular events) and the limited impact of glucose reduction in patients with diabetes on cardiovascular events do not support blood glucose as a major cause of cardiovascular disease. In this review, we discuss the relationship between hyperglycaemia and a hypercoagulable state in diabetes and the implications of this relationship for the treatment of patients with diabetes, who also commonly have hypertension.
Export Options
About this article
Cite this article as:
Lim S. Hoong, MacFadyen J. Robert, Bakris George and Lip Y.H. Gregory, The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843322
DOI https://dx.doi.org/10.2174/138161206776843322 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Current Drug Targets Serotonin Reuptake Inhibitors and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Progress in the Development of Melanocortin Receptor Selective Ligands
Current Pharmaceutical Design Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥
Current Vascular Pharmacology Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature
Current Hypertension Reviews Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Atherosclerosis
Current Stem Cell Research & Therapy Chronic Cerebral Hypoperfusion Protects Against Acute Focal Ischemia,Improves Motor Function, and Results in Vascular Remodeling
Current Neurovascular Research Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013)
Current Vascular Pharmacology Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry